MohiniRanganathanMD

Psychiatry • West Haven, CT

Assistant Professor, Psychiatry, Yale University School of Medicine

Join to view full profile

Dr. Ranganathan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Ranganathan's full profile

Already have an account?

Office
950 Campbell Ave
Psychiatry Service/116a
West Haven, CT 06516
Phone+1 203-932-5711
Is this information wrong?

Education & Training

SUNY Downstate Health Sciences UniversityResidency, Psychiatry, 2002 - 2005
Calicut Medical CollegeClass of 1999

Certifications & Licensure

CT State Medical License 2006 - 2024
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia Start of enrollment: 2009 Feb 01
Completed
Phase 2
Effects of Salvinorin A in Healthy Controls Start of enrollment: 2009 Feb 12
Completed
Early Phase 1
The Effects of Cannabidiol and ∆-9-THC in Humans Start of enrollment: 2010 Feb 01
Completed
Early Phase 1
Cannabinoid Augmentation of Fear Response in Humans Start of enrollment: 2012 Jul 17
Completed
Early Phase 1
Probing the Cannabinoid System in Individuals With a Family History of Psychosis Start of enrollment: 2014 Jan 01
Active, not recruiting
Early Phase 1
Open Label Ketamine Treatment for Major Depressive Disorder in Veterans Start of enrollment: 2017 Jan 31
Completed
Phase 2
The Neural Correlates of Cannabis Use Start of enrollment: 2016 Dec 01
Completed
CB1R in Synthetic Psychoactive Cannabinoids Start of enrollment: 2018 May 01
Active, not recruiting
Not Applicable
BXCL501 for Agitation in Schizophrenia Start of enrollment: 2020 Mar 09
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Clinical Outcomes of Intravenous Ketamine Treatment for Depression in the VA Health System.
Gilmer, W., Paul N Pfeiffer, Jamarie Geller, Dara Ganoczy, Jennifer Jagusch, John Carty, Fe Erlita D Festin, William S Gilmer, Brian Martis, Mohini Ranganathan, Ilse R...> ;The Journal of Clinical Psychiatry. 2024 Jan 8
Sex Differences in the Acute Effects of Oral THC: A Randomized, Placebo-Controlled, Crossover Human Laboratory Study.
Ardavan Mohammad Aghaei, Lia Urban Spillane, Brian Pittman, L Taylor Flynn, Joao P De Aquino, Anahita Bassir Nia, Mohini Ranganathan> ;Medrxiv. 2024 Mar 12
Delta-9-tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within-subject, randomized, placebo-c...
Joao P De Aquino, Julia Meyerovich, Catherine Z Xie, Mohini Ranganathan, Peggy Compton, Brian Pittman, Michael Rogan, Mehmet Sofuoglu> ;Addiction Biology. 2023 Sep 1
Illness Phase as a Key Assessment and Intervention Window for Psychosis.
Christian G Kohler, Daniel H Wolf, Anissa Abi-Dargham, Alan Anticevic, Youngsun T Cho, Clara Fonteneau, Roberto Gil, Ragy R Girgis, David L Gray, Jack Grinband, Jonath...> ;Biological Psychiatry Global Open Science. 2023 Jul 1
Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia.
Toral S Surti, Mohini Ranganathan, Jason K Johannesen, Ralitza Gueorguieva, Emma Deaso, Joshua G Kenney, John H Krystal, Deepak Cyril D'Souza> ;Schizophrenia Research. 2023 Jun 1
1 citations
Preliminary study of the interactive effects of THC and ethanol on self-reported ability and simulated driving, subjective effects, and cardiovascular responses.
Ashley M Schnakenberg Martin, L Taylor Flynn, Esra Sefik, Christina Luddy, Jose Cortes-Briones, Patrick D Skosnik, Brian Pittman, Mohini Ranganathan, Deepak Cyril D'Souza> ;Psychopharmacology. 2023 Jun 1
Peripheral signature of altered synaptic integrity in young onset cannabis use disorder: A proteomic study of circulating extracellular vesicles.
Suhas Ganesh, TuKiet T Lam, Rolando Garcia-Milian, Deepak Cyril D'Souza, Angus C Nairn, Katya Elgert, Erez Eitan, Mohini Ranganathan> ;The World Journal of Biological Psychiatry. 2023 Apr 13
2 citations
Age, gender and body-mass-index relationships with in vivo CBreceptor availability in healthy humans measured with [C]OMAR PET.
Rajiv Radhakrishnan, Patrick D Worhunsky, Ming-Qiang Zheng, Soheila Najafzadeh, Jean-Dominique Gallezot, Beata Planeta, Shannan Henry, Nabeel Nabulsi, Mohini Ranganath...> ;Neuroimage. 2022 Dec 1
44 citations
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized ...
David W Oslin, Kevin G Lynch, Mei-Chiung Shih, Erin P Ingram, Laura O Wray, Sara R Chapman, Henry R Kranzler, Joel Gelernter, Jeffrey M Pyne, Annjanette Stone, Scott L...> ;JAMA. 2022 Jul 12
Correction to: Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-b...
Chadi G Abdallah, John D Roache, Ralitza Gueorguieva, Lynnette A Averill, Stacey Young-McCaughan, Paulo R Shiroma, Prerana Purohit, Antoinette Brundige, William Murff,...> ;Neuropsychopharmacology. 2022 Jul 1
32 citations
Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomize...
Chadi G Abdallah, John D Roache, Ralitza Gueorguieva, Lynnette A Averill, Stacey Young-McCaughan, Paulo R Shiroma, Prerana Purohit, Antoinette Brundige, William Murff,...> ;Neuropsychopharmacology. 2022 Jul 1
40 citations
Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder.
Deepak Cyril D'Souza, Shariful A Syed, L Taylor Flynn, Hamideh Safi-Aghdam, Nicholas V Cozzi, Mohini Ranganathan> ;Neuropsychopharmacology. 2022 Sep 1
5 citations
Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC).
Anahita Bassir Nia, Maria J Orejarena, Leigh Flynn, Christina Luddy, Deepak Cyril D'Souza, Patrick D Skosnik, Brian Pittman, Mohini Ranganathan> ;Psychopharmacology. 2022 May 1
1 citations
Multimodal Correlates of Cannabis Use among U.S. Veterans with Bipolar Disorder: An Integrated Study of Clinical, Cognitive, and Functional Outcomes.
Alexandria Selloni, Gagandeep Bhatia, Mohini Ranganathan, Joao P De Aquino> ;Journal of Dual Diagnosis. 2022 Apr 17
16 citations
mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression.
Lynnette A Averill, Christopher L Averill, Ralitza Gueorguieva, Samar Fouda, Mohamed Sherif, Kyung-Heup Ahn, Mohini Ranganathan, Deepak Cyril D'Souza, Steven M Southwi...> ;Journal of Affective Disorders. 2022 Apr 15
16 citations
Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis.
Deepak Cyril D'Souza, Marta DiForti, Suhas Ganesh, Tony P George, Wayne Hall, Carsten Hjorthøj, Oliver Howes, Matcheri Keshavan, Robin M Murray, Timothy B Nguyen, Godf...> ;The World Journal of Biological Psychiatry. 2022 Dec 1
Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior.
Suhas Ganesh, Jose Cortes-Briones, Ashley M Schnakenberg Martin, Patrick D Skosnik, Deepak C D'Souza, Mohini Ranganathan> ;Cannabis and Cannabinoid Research. 2023 Oct 1
9 citations
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
Anissa Abi-Dargham, Jonathan A. Javitch, Mark Slifstein, Alan Anticevic, Monica E. Calkins, Youngsun T. Cho, Clara Fonteneau, Roberto Gil, Ragy R. Girgis, Raquel E. Gu...> ;Schizophrenia Bulletin. 2021 Aug 23
44 citations
In vivo evidence of lower synaptic vesicle density in schizophrenia.
Rajiv Radhakrishnan, Patrick D. Skosnik, Mohini Ranganathan, Mika Naganawa, Takuya Toyonaga, Sjoerd J. Finnema, Ansel T. Hillmer, Irina Esterlis, Yiyun Huang, Nabeel N...> ;Molecular Psychiatry. 2021 Jun 16
1 citations
Exocannabinoids, Endocannabinoids, and Psychosis.
Rajiv Radhakrishnan, Mohini Ranganathan, Patrick D. Skosnik, Deepak Cyril D'Souza> ;Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. 2021 Jun 1
18 citations
Analysis of circulating exosomes reveals a peripheral signature of astrocytic pathology in schizophrenia.
Mohini Ranganathan, Mohammad Rahman, Suhas Ganesh, Deepak Cyril D'Souza, Patrick D. Skosnik, Rajiv Radhakrishnan, Surbhi Pathania, Thalachallour Mohanakumar> ;The World Journal of Biological Psychiatry. 2021 Apr 28
17 citations
A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants
Chadi G. Abdallah, Kyung-Heup Ahn, Lynnette A. Averill, Samaneh Nemati, Christopher L. Averill, Samar Fouda, Mohini Ranganathan, Peter Morgan, Deepak Cyril D'Souza, Da...> ;Neuropsychopharmacology. 2021 Jan 1
21 citations
Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.
Suhas Ganesh, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, Deepak Cyril D'Souza> ;The International Journal of Neuropsychopharmacology. 2020 Dec 3
Alterations in the Endocannabinoid System in Schizophrenia.
Mohini Ranganathan, Deepak Cyril D'Souza> ;Biological Psychiatry. 2020 Nov 1
29 citations
Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder.
Deepak Cyril D'Souza, Rajiv Radhakrishnan, Mika Naganawa, Suhas Ganesh, Nabeel Nabulsi, Soheila Najafzadeh, Jim Ropchan, Mohini Ranganathan, Jose Cortes-Briones, Yiyun...> ;Molecular Psychiatry. 2021 Jul 1
Join now to see all

Journal Articles

Association of Ketamine with Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia
Mohini Ranganathan, John H Krystal, JAMA Network Open

Authored Content

Association of Ketamine with Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding SchizophreniaMay 2020
Association of Ketamine with Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding SchizophreniaMay 2020

Press Mentions

Cannabidiol Drugs Clinical Trial Outcomes and Adverse EffectsFebruary 25th, 2020
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) (FAAH-I MULTI)December 29th, 2017
Why Some People Can't Handle Their WeedMay 15th, 2017
Join now to see all

Hospital Affiliations

Veterans Affairs Connecticut Healthcare SystemWest Haven, Connecticut